Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo Controlled, First-in-human Study to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN360 in Subjects With Elevated Lipoprotein(a)

NCT04606602 is registered in ClinicalTrials.gov with Silence Therapeutics plc as lead sponsor.

NCT NCT04606602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04606602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo Controlled, First-in-human Study to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN360 in Subjects With Elevated Lipoprotein(a)
Lead sponsor
Silence Therapeutics plc
Phase
Phase 1
Overall status
Completed
Start date
November 18, 2020
Completion date
August 23, 2023
Enrollment
70 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias, elevated lp(a), hyperlipidemias